59. Rapid Alert: Spurious/Falsified Drug Product i.e. Sandostatin LAR 20mg injection (Batch # 380531)

Rapid Alert

Spurious/Falsified Drug Product i.e. Sandostatin LAR 20mg injection (Batch # 380531)
DRAP Alert NoNo I/S/11-26-59
Action Date17th November, 2026
Target AudienceField Offices of DRAP and Provincial Drug Control departments.
Healthcare Professionals
Consumers
Problem StatementM/s Nouveaux Pharma Limited, Karachi has informed the availability of their product i.e. Sandostatin LAR 20mg Injection (Batch # 380531) in the market which was intended for Turkish Market. The below-mentioned product (Batch # 380531) was not supplied through legal channels into Pakistan.
Following are the details:
Risk StatementThe use of the above-mentioned drug product may pose serious safety and quality concerns for public health including therapeutic failure, adverse health consequences, or exposure to unknown safety risks.
Action InitiatedThe Regulatory Field Force of DRAP and Provincial Drug Control Departments have been asked to conduct surveillance activities throughout the supply chain to confiscate the falsified product.
Advice for Healthcare ProfessionalsDRAP requests healthcare professionals to have increased vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by above mentioned product. Any adverse events or quality problems experienced with the use of these products should be reported to  National or Provincial pharmacovigilance centers using Adverse Event Reporting Form or online through this link.  Further information on reporting problems to DRAP is available on this link.
Advice for ConsumersConsumers should not use the above-mentioned product and should contact their physician or healthcare provider(s) if they have experienced any problem related to taking or using the above mentioned products and should report the incident to the Drug Regulatory Authority of Pakistan / National Pharmacovigilance Centre. All therapeutic goods must be obtained from licensed pharmacies and other authorized/licensed retail outlets. The authenticity and condition of products should be carefully checked. Seek advice from your pharmacists or other healthcare professionals in case of any doubt.

58. Rapid Alert: Spurious/Adulterated Gabica Capsule 300mg

Rapid Alert

Spurious/Adulterated Gabica Capsule 300mg
DRAP Alert NoNo I/S/11-26-58
Action Date17th November, 2026
Target AudienceRegulatory Field Force of DRAP and Provincial Drug Control departments.
Healthcare Professionals
Consumers
Problem StatementDrug Testing Laboratories, Punjab informed that the samples of below mentioned drug products have been declared as ‘Spurious/Adulterated’. The manufacturer i.e M/s Getz Pharma (Pvt) Ltd., Karachi has disowned the product.
Following are the details of the Spurious therapeutic product.
Following are the details:
Risk StatementThe use of the above-mentioned Spurious/adulterated drug product may pose serious safety and quality concerns for public health including therapeutic failure, adverse health consequences, or exposure to unknown safety risks.
Action InitiatedThe Regulatory Field Force of DRAP and Provincial Drug Control Departments have been asked to conduct surveillance activities throughout the supply chain to confiscate the falsified product.
Advice for Healthcare ProfessionalsDRAP requests healthcare professionals to have increased vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by above mentioned product. Any adverse events or quality problems experienced with the use of these products should be reported to  National or Provincial pharmacovigilance centers using Adverse Event Reporting Form or online through this link.  Further information on reporting problems to DRAP is available on this link.
Advice for ConsumersConsumers should not use the above-mentioned product and should contact their physician or healthcare provider(s) if they have experienced any problem related to taking or using the above mentioned products and should report the incident to the Drug Regulatory Authority of Pakistan / National Pharmacovigilance Centre. All therapeutic goods must be obtained from licensed pharmacies and other authorized/licensed retail outlets. The authenticity and condition of products should be carefully checked. Seek advice from your pharmacists or other healthcare professionals in case of any doubt.

57. Recall Alert: Drug product Declared as Substandard by Central Drugs Laboratories (CDL) Karachi

Recall Alert

Therapeutic Goods (s) Affected: –

56. Recall Alert: Drug products declared Substandard/Misbranded by Drug Testing laboratories Punjab

Recall Alert (Veterinary)

Therapeutic Goods (s) Affected: –

55. Rapid Alert: Drug products declared Substandard/Adulterated by Drug Testing laboratories Punjab

Recall Alert

Therapeutic Goods (s) Affected: –

54. Recall Alert: Drug products declared Substandard by Drug Testing laboratories Punjab

Recall Alert

Therapeutic Goods (s) Affected: –

53. Rapid Alert: Spurious/Falsified Hexaxim Vaccine (Batch # X3H421VA)

Rapid Alert

Spurious/Falsified Hexaxim Vaccine (Batch # X3H421VA)
DRAP Alert NoNo I/S/11-26-53
Action Date12th November, 2026
Target AudienceRegulatory Field Force of DRAP and Provincial Drug Control departments.
Healthcare Professionals
Consumers
Problem StatementM/s Hoechst Pakistan Limited Karachi has informed that the below-mentioned product in vial presentation is not registered nor imported into Pakistan for distribution. The product is registered as Pre-filled Syringe. The availability and use of the below-mentioned Spurious/Falsified presentation i.e. Vial may pose serious health consequences to the patients including therapeutic failure and serious unwanted effects. Following are the details:
Risk StatementThe use of the above-mentioned Spurious/Falsified drug product may pose serious safety and quality concerns for public health including therapeutic failure, adverse health consequences, or exposure to unknown safety risks.
Action InitiatedThe Regulatory Field Force of DRAP and Provincial Drug Control Departments have been asked to conduct surveillance activities throughout the supply chain to confiscate the falsified product.
Advice for Healthcare ProfessionalsDRAP requests healthcare professionals to have increased vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by above mentioned product. Any adverse events or quality problems experienced with the use of these products should be reported to  National or Provincial pharmacovigilance centers using Adverse Event Reporting Form or online through this link.  Further information on reporting problems to DRAP is available on this link.
Advice for ConsumersConsumers should not use the above-mentioned product and should contact their physician or healthcare provider(s) if they have experienced any problem related to taking or using the above mentioned products and should report the incident to the Drug Regulatory Authority of Pakistan / National Pharmacovigilance Centre. All therapeutic goods must be obtained from licensed pharmacies and other authorized/licensed retail outlets. The authenticity and condition of products should be carefully checked. Seek advice from your pharmacists or other healthcare professionals in case of any doubt.

52. Rapid Alert: Spurious/Falsified Axtin Soft Gels (Batch # AXAF2301)

Rapid Alert

Spurious/Falsified Axtin Soft Gels (Batch # AXAF2301)
DRAP Alert NoNo I/S/11-26-52
Action Date12th November, 2026
Target AudienceRegulatory Field Force of DRAP and Provincial Drug Control departments.
Healthcare Professionals
Consumers
Problem StatementM/s Scotmann Pharmaceuticals (Health & OTC Division) (Nutraceuticals), 5-D, I-10/3 Industrial Area, Islamabad, the authorized manufacturer of Axtin Softgel, has reported the availability of a spurious therapeutic product in the market bearing a brand name and packaging similar to its duly enlisted product. The resemblance may mislead consumers and stakeholders regarding the authenticity of the product. Following are the details:
Risk StatementThe use of the above-mentioned Spuroiustherapeutic product may pose serious safety and quality concerns for public health including therapeutic failure, adverse health consequences, or exposure to unknown safety risks.
Action InitiatedThe Regulatory Field Force of DRAP and Provincial Drug Control Departments have been asked to conduct surveillance activities throughout the supply chain to confiscate the falsified product.
Advice for Healthcare ProfessionalsDRAP requests healthcare professionals to have increased vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by above mentioned product. Any adverse events or quality problems experienced with the use of these products should be reported to  National or Provincial pharmacovigilance centers using Adverse Event Reporting Form or online through this link.  Further information on reporting problems to DRAP is available on this link.
Advice for ConsumersConsumers should not use the above-mentioned product and should contact their physician or healthcare provider(s) if they have experienced any problem related to taking or using the above mentioned products and should report the incident to the Drug Regulatory Authority of Pakistan / National Pharmacovigilance Centre. All therapeutic goods must be obtained from licensed pharmacies and other authorized/licensed retail outlets. The authenticity and condition of products should be carefully checked. Seek advice from your pharmacists or other healthcare professionals in case of any doubt.

50. Rapid Alert: Adulterated/Substandard/Spurious/Unregistered Drug Products

Rapid Alert

Adulterated/Substandard/Spurious/Unregistered Drug Products
DRAP Alert NoNo I/S/11-05-50
Action Date5th November, 2026
Target AudienceField Offices of DRAP and Provincial Drug Control departments.
Healthcare Professionals
Consumers
Problem StatementDrug Testing Laboratory (DTL) Sindh, Karachi has declared the samples of below-mentioned drug products have been declared as Adulterated/Substandard/Spurious/Unregistered as defined in Section 3(a)(i)(zb)(i)(iv), 3(a)(i)(zb)(i)(iv),(zz) and 23(1)(a)(i)(iii)(v) & (vii) of the Drugs Act, 1976.
Risk StatementThe use of the above-mentioned Spurious/Adulterated/Substandard/Unregistered drug products may pose serious safety and quality concerns for public health including therapeutic failure, adverse health consequences, or exposure to unknown safety risks.
Action InitiatedThe Regulatory Field Force of Provincial Drug Control Departments have been asked to conduct surveillance activities throughout the supply chain to confiscate the falsified product.
Advice for Healthcare ProfessionalsDRAP requests healthcare professionals to have increased vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by above mentioned product. Any adverse events or quality problems experienced with the use of these products should be reported to  National or Provincial pharmacovigilance centers using Adverse Event Reporting Form or online through this link.  Further information on reporting problems to DRAP is available on this link.
Advice for ConsumersConsumers should not use the above-mentioned product and should contact their physician or healthcare provider(s) if they have experienced any problem related to taking or using the above mentioned products and should report the incident to the Drug Regulatory Authority of Pakistan / National Pharmacovigilance Centre. All therapeutic goods must be obtained from licensed pharmacies and other authorized/licensed retail outlets. The authenticity and condition of products should be carefully checked. Seek advice from your pharmacists or other healthcare professionals in case of any doubt.

51. Rapid Alert: Drug Products Declared as “Unregistered” by Central Drugs Laboratory, Karachi

Rapid Alert

Drug Products Declared as “Unregistered” by Central Drugs Laboratory (CDL), Karachi
DRAP Alert NoNo I/S/11-05-51
Action Date5th November, 2026
Target AudienceField Offices of DRAP and Provincial Drug Control departments
Healthcare Professionals
Consumers
Problem StatementCentral Drugs Laboratory (CDL), Karachi has declared the samples of below-mentioned drug products as “Unregistered”. Following are the details:
Risk StatementThe use of the above-mentioned Unregistered drug products may pose serious safety and quality concerns for public health including therapeutic failure, adverse health consequences, or exposure to unknown safety risks.
Action InitiatedThe Regulatory Field Force of Provincial Drug Control Departments have been asked to conduct surveillance activities throughout the supply chain to confiscate the falsified product.
Advice for Healthcare ProfessionalsDRAP requests healthcare professionals to have increased vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by above mentioned product. Any adverse events or quality problems experienced with the use of these products should be reported to  National or Provincial pharmacovigilance centers using Adverse Event Reporting Form or online through this link.  Further information on reporting problems to DRAP is available on this link.
Advice for ConsumersConsumers should not use the above-mentioned product and should contact their physician or healthcare provider(s) if they have experienced any problem related to taking or using the above mentioned products and should report the incident to the Drug Regulatory Authority of Pakistan / National Pharmacovigilance Centre. All therapeutic goods must be obtained from licensed pharmacies and other authorized/licensed retail outlets. The authenticity and condition of products should be carefully checked. Seek advice from your pharmacists or other healthcare professionals in case of any doubt.